| September 1, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| September 1, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| September 1, 2026 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| September 1, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| September 1, 2026 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| September 1, 2026 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| September 1, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| September 1, 2026 |
NVS |
6-K filed: Foreign issuer report |
Filing |
— |
| September 1, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 1, 2026 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| September 1, 2026 |
INCY |
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients |
Trial Milestone |
Phase 3 |
| September 1, 2026 |
RVMD |
8-K filed: Material agreement |
Corporate |
— |
| September 1, 2026 |
BMRN |
8-K filed: Other event |
Filing |
— |
| September 1, 2026 |
INBS |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 1, 2026 |
MRNA |
8-K filed: Material agreement, Other event |
Corporate |
— |
| September 1, 2026 |
IVVD |
8-K filed: Leadership change, Other event |
Corporate |
— |
| September 1, 2026 |
NVCR |
8-K filed: Other event |
Filing |
— |
| September 1, 2026 |
ALMS |
8-K filed: Other event |
Filing |
— |
| September 1, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| September 1, 2026 |
VRTX |
8-K filed: Leadership change |
Corporate |
— |
| September 1, 2026 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| September 2, 2026 |
JNJ |
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms |
Trial Milestone |
Phase 1 |
| September 2, 2026 |
RARE |
8-K filed: Other event |
Filing |
— |
| September 2, 2026 |
INBS |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| September 2, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| September 2, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| September 2, 2026 |
COGT |
8-K filed: Material agreement |
Corporate |
— |
| September 2, 2026 |
QURE |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 2, 2026 |
TCRX |
8-K filed: Listing / standard notice, Leadership change, Reg FD disclosure, Other event |
Corporate |
— |
| September 2, 2026 |
ALLO |
8-K filed: Leadership change |
Corporate |
— |
| September 3, 2026 |
NVS |
Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease |
Trial Milestone |
Phase 4 |
| September 3, 2026 |
NVS |
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer |
Trial Milestone |
Phase 3 |
| September 3, 2026 |
ABBV |
A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult Participants |
Trial Milestone |
Phase 1 |
| September 3, 2026 |
ABBV |
A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult Participants |
Trial Milestone |
Phase 1 |
| September 3, 2026 |
ABBV |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 3, 2026 |
NVO |
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation |
Trial Milestone |
Phase 3 |
| September 3, 2026 |
SMMT |
8-K filed: Other event |
Filing |
— |
| September 3, 2026 |
TEVA |
8-K filed: Other event |
Filing |
— |
| September 3, 2026 |
LQDA |
8-K filed: Other event |
Filing |
— |
| September 3, 2026 |
PCVX |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| September 3, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| September 3, 2026 |
LBRX |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| September 3, 2026 |
CLYM |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 3, 2026 |
ACIU |
6-K filed: Foreign issuer report |
Filing |
— |
| September 4, 2026 |
NVS |
6-K filed: Foreign issuer report |
Filing |
— |
| September 4, 2026 |
IONS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 4, 2026 |
IONS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 4, 2026 |
VNDA |
Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) |
Trial Milestone |
Phase 3 |
| September 4, 2026 |
NTLA |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| September 7, 2026 |
EWTX |
Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) |
Trial Milestone |
Phase 2 |
| September 8, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| September 8, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| September 8, 2026 |
NVS |
6-K filed: Foreign issuer report |
Filing |
— |
| September 8, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 8, 2026 |
INCY |
A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants |
Trial Milestone |
Phase 1 |
| September 8, 2026 |
SVA |
Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine |
Trial Milestone |
Phase 4 |
| September 8, 2026 |
MIRM |
8-K filed: Leadership change |
Corporate |
— |
| September 8, 2026 |
DFTX |
8-K filed: Other event |
Filing |
— |
| September 8, 2026 |
OCGN |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 8, 2026 |
NTLA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 8, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| September 8, 2026 |
NKTR |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 8, 2026 |
IKT |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 8, 2026 |
BLTE |
6-K filed: Foreign issuer report |
Filing |
— |
| September 8, 2026 |
PHVS |
6-K filed: Foreign issuer report |
Filing |
— |
| September 8, 2026 |
PHVS |
6-K filed: Foreign issuer report |
Filing |
— |
| September 8, 2026 |
UTHR |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| September 8, 2026 |
RLMD |
8-K filed: Other event |
Filing |
— |
| September 8, 2026 |
AMLX |
8-K filed: Material agreement |
Corporate |
— |
| September 8, 2026 |
KURA |
8-K filed: Leadership change |
Corporate |
— |
| September 8, 2026 |
SYRE |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 8, 2026 |
CATX |
8-K filed: Other event |
Filing |
— |
| September 8, 2026 |
BRVE |
Quarterly results filed (8-K) |
Earnings |
— |
| September 8, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| September 8, 2026 |
IRON |
Study of Bitopertin in Participants With EPP or XLP (APOLLO) |
Trial Milestone |
Phase 3 |
| September 8, 2026 |
XFOR |
8-K filed: Other event |
Filing |
— |
| September 8, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| September 8, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| September 8, 2026 |
KPRX |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| September 8, 2026 |
SXTP |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 9, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| September 9, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| September 9, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| September 9, 2026 |
INBS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 9, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| September 9, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| September 9, 2026 |
CADL |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 9, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| September 9, 2026 |
IMUX |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 9, 2026 |
TENX |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 9, 2026 |
IRD |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 9, 2026 |
NVCR |
8-K filed: Leadership change |
Corporate |
— |
| September 9, 2026 |
PRQR |
6-K filed: Foreign issuer report |
Filing |
— |
| September 9, 2026 |
KURA |
8-K filed: Other event |
Filing |
— |
| September 9, 2026 |
TYRA |
8-K filed: Other event |
Filing |
— |
| September 9, 2026 |
TTRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 9, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| September 9, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| September 9, 2026 |
XFOR |
8-K filed: Other event |
Filing |
— |
| September 9, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| September 9, 2026 |
GOSS |
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) |
Trial Milestone |
Phase 2 |
| September 9, 2026 |
GOSS |
8-K filed: Other event |
Filing |
— |
| September 10, 2026 |
GSK |
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202 |
Trial Milestone |
Phase 2 |
| September 10, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| September 10, 2026 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| September 10, 2026 |
QNRX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 10, 2026 |
EYPT |
8-K filed: Other event |
Filing |
— |
| September 10, 2026 |
CADL |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| September 10, 2026 |
LYEL |
8-K filed: Other event |
Filing |
— |
| September 10, 2026 |
ONCY |
8-K filed: Other event |
Filing |
— |
| September 10, 2026 |
TTRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 10, 2026 |
NTHI |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| September 10, 2026 |
BLRX |
6-K filed: Foreign issuer report |
Filing |
— |
| September 10, 2026 |
IRON |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 10, 2026 |
LPCN |
8-K filed: Other event |
Filing |
— |
| September 10, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| September 10, 2026 |
CNSY |
8-K filed: Material agreement, Other event |
Corporate |
— |
| September 11, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| September 11, 2026 |
EXEL |
8-K filed: Other event |
Filing |
— |
| September 11, 2026 |
INBS |
8-K filed: Other event |
Filing |
— |
| September 11, 2026 |
KPTI |
8-K filed: Material agreement, Other event |
Corporate |
— |
| September 11, 2026 |
ACAD |
8-K filed: Other event |
Filing |
— |
| September 11, 2026 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| September 11, 2026 |
TEVA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 11, 2026 |
IMUX |
8-K filed: Leadership change |
Corporate |
— |
| September 11, 2026 |
IRD |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 11, 2026 |
PHAT |
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks |
Trial Milestone |
Phase 2 |
| September 11, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| September 11, 2026 |
LPCN |
8-K filed: Other event |
Filing |
— |
| September 11, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| September 11, 2026 |
TCRX |
8-K filed: Leadership change |
Corporate |
— |
| September 11, 2026 |
GOSS |
8-K filed: Other event |
Filing |
— |
| September 11, 2026 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| September 11, 2026 |
CLLS |
6-K/A filed: Foreign issuer report |
Filing |
— |
| September 12, 2026 |
NVO |
A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes |
Trial Milestone |
Phase 1 |
| September 14, 2026 |
AZN |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| September 14, 2026 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| September 14, 2026 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| September 14, 2026 |
SNY |
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX |
Trial Milestone |
Phase 3 |
| September 14, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 14, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| September 14, 2026 |
BMRN |
8-K filed: Leadership change |
Corporate |
— |
| September 14, 2026 |
SMMT |
8-K filed: Other event |
Filing |
— |
| September 14, 2026 |
DFTX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 14, 2026 |
TEVA |
8-K filed: Other event |
Filing |
— |
| September 14, 2026 |
CABA |
8-K filed: Other event |
Filing |
— |
| September 14, 2026 |
IMCR |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 14, 2026 |
CRBP |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 14, 2026 |
SRRK |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 14, 2026 |
BFRI |
8-K filed: Other event |
Filing |
— |
| September 14, 2026 |
CATX |
8-K filed: Other event |
Filing |
— |
| September 14, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| September 14, 2026 |
LPCN |
8-K filed: Other event |
Filing |
— |
| September 14, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 14, 2026 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| September 14, 2026 |
CGEM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 14, 2026 |
SXTP |
8-K filed: Other event |
Filing |
— |
| September 14, 2026 |
QTTB |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 15, 2026 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| September 15, 2026 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| September 15, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 15, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 15, 2026 |
ABBV |
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors |
Trial Milestone |
Phase 1 |
| September 15, 2026 |
ABBV |
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab |
Trial Milestone |
Phase 3 |
| September 15, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| September 15, 2026 |
ARGX |
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy |
Trial Milestone |
Phase 3 |
| September 15, 2026 |
VNDA |
Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis |
Trial Milestone |
Phase 2 |
| September 15, 2026 |
VNDA |
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye |
Trial Milestone |
Phase 2 |
| September 15, 2026 |
JAZZ |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 15, 2026 |
BMRN |
8-K filed: Other event |
Filing |
— |
| September 15, 2026 |
INBS |
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer |
Trial Milestone |
Phase 2/Phase 3 |
| September 15, 2026 |
ALKS |
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder |
Trial Milestone |
Phase 3 |
| September 15, 2026 |
SMMT |
8-K filed: Other event |
Filing |
— |
| September 15, 2026 |
KPTI |
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis |
Trial Milestone |
Phase 2 |
| September 15, 2026 |
ZBIO |
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus |
Trial Milestone |
Phase 2 |
| September 15, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| September 15, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| September 15, 2026 |
CYTK |
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF |
Trial Milestone |
Phase 2 |
| September 15, 2026 |
RGNX |
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) |
Trial Milestone |
Phase 2/Phase 3 |
| September 15, 2026 |
CORT |
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies |
Trial Milestone |
Phase 1/Phase 2 |
| September 15, 2026 |
SUPN |
Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) |
Trial Milestone |
Phase 3 |
| September 15, 2026 |
LNTH |
PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer |
Trial Milestone |
Phase 4 |
| September 15, 2026 |
GKOS |
Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis |
Trial Milestone |
Phase 2 |
| September 15, 2026 |
LBRX |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| September 15, 2026 |
SNDX |
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) |
Trial Milestone |
Phase 2 |
| September 15, 2026 |
AVIR |
C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV |
Trial Milestone |
Phase 3 |
| September 15, 2026 |
ABVX |
Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation |
Trial Milestone |
Phase 1 |
| September 15, 2026 |
VERA |
Monthly Dosing of Atacicept in IgAN |
Trial Milestone |
Phase 2 |
| September 15, 2026 |
VERA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 15, 2026 |
SRRK |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 15, 2026 |
TNGX |
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors |
Trial Milestone |
Phase 1/Phase 2 |
| September 15, 2026 |
TLSA |
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients |
Trial Milestone |
Phase 2 |
| September 15, 2026 |
ORIC |
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration |
Trial Milestone |
Phase 1/Phase 2 |
| September 15, 2026 |
TYRA |
8-K filed: Other event |
Filing |
— |
| September 15, 2026 |
TRAW |
Study of TRX-100 Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy Volunteers |
Trial Milestone |
Phase 1 |
| September 15, 2026 |
ABEO |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 15, 2026 |
RADX |
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors |
Trial Milestone |
Phase 1 |
| September 15, 2026 |
COYA |
8-K filed: Other event |
Filing |
— |
| September 15, 2026 |
WVE |
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD |
Trial Milestone |
Phase 1/Phase 2 |
| September 15, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| September 15, 2026 |
TPST |
8-K filed: Material agreement |
Corporate |
— |
| September 15, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| September 15, 2026 |
MAZE |
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease |
Trial Milestone |
Phase 2 |
| September 15, 2026 |
CGEM |
A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma |
Trial Milestone |
Phase 1 |
| September 16, 2026 |
AMGN |
Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity |
Trial Milestone |
Phase 1 |
| September 16, 2026 |
ALKS |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| September 16, 2026 |
TEVA |
8-K filed: Material agreement |
Corporate |
— |
| September 16, 2026 |
AVLN |
8-K filed: Leadership change |
Corporate |
— |
| September 16, 2026 |
HALO |
8-K filed: Other event |
Filing |
— |
| September 16, 2026 |
TPST |
8-K filed: Other event |
Filing |
— |
| September 16, 2026 |
LPCN |
8-K filed: Other event |
Filing |
— |
| September 16, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| September 16, 2026 |
HURA |
8-K filed: Leadership change |
Corporate |
— |
| September 16, 2026 |
GOSS |
8-K filed: Leadership change |
Corporate |
— |
| September 17, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| September 17, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| September 17, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| September 17, 2026 |
RARE |
8-K filed: Other event |
Filing |
— |
| September 17, 2026 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| September 17, 2026 |
NTHI |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 17, 2026 |
TPST |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| September 17, 2026 |
HURA |
8-K/A filed: Leadership change |
Corporate |
— |
| September 17, 2026 |
FTH |
8-K filed: Leadership change |
Corporate |
— |
| September 18, 2026 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| September 18, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| September 18, 2026 |
HALO |
8-K filed: Other event |
Filing |
— |
| September 18, 2026 |
BYSI |
8-K filed: Listing / standard notice |
Corporate |
— |
| September 18, 2026 |
OTLK |
8-K filed: Other event |
Filing |
— |
| September 18, 2026 |
MBRX |
8-K filed: Listing / standard notice |
Corporate |
— |
| September 21, 2026 |
AZN |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| September 21, 2026 |
AZN |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| September 21, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| September 21, 2026 |
ALKS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 21, 2026 |
TVTX |
8-K filed: Leadership change |
Corporate |
— |
| September 21, 2026 |
LNTH |
8-K filed: Other event |
Filing |
— |
| September 21, 2026 |
ABVX |
6-K filed: Foreign issuer report |
Filing |
— |
| September 21, 2026 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| September 21, 2026 |
RXRX |
8-K filed: Material agreement |
Corporate |
— |
| September 21, 2026 |
NTHI |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 21, 2026 |
ETRA |
8-K filed: Other event |
Filing |
— |
| September 21, 2026 |
CRDL |
CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) |
Trial Milestone |
Phase 3 |
| September 22, 2026 |
LLY |
A Study of Eltrekibart (LY3041658) in Healthy Participants |
Trial Milestone |
Phase 1 |
| September 22, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| September 22, 2026 |
ONC |
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia |
Trial Milestone |
Phase 2 |
| September 22, 2026 |
MRNA |
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age |
Trial Milestone |
Phase 1/Phase 2 |
| September 22, 2026 |
QNRX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 22, 2026 |
CLDX |
8-K filed: Other event |
Filing |
— |
| September 22, 2026 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| September 22, 2026 |
VTGN |
8-K filed: Other event |
Filing |
— |
| September 22, 2026 |
LONA |
8-K filed: Other event |
Filing |
— |
| September 22, 2026 |
LXEO |
8-K filed: Material agreement, Other event |
Corporate |
— |
| September 22, 2026 |
HALO |
8-K filed: Material agreement |
Corporate |
— |
| September 22, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| September 23, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| September 23, 2026 |
ARGX |
A Study to Assess the Bioequivalence of Efgartigimod PH20 SC Between Autoinjector and Prefilled Syringe in Healthy Adult Participants |
Trial Milestone |
Phase 1 |
| September 23, 2026 |
IONS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 23, 2026 |
JAZZ |
8-K filed: Material agreement |
Corporate |
— |
| September 23, 2026 |
BSX |
8-K filed: Leadership change |
Corporate |
— |
| September 23, 2026 |
SRPT |
8-K filed: Material agreement |
Corporate |
— |
| September 23, 2026 |
RGNX |
8-K filed: Material agreement |
Corporate |
— |
| September 23, 2026 |
CORT |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| September 23, 2026 |
MGTX |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| September 23, 2026 |
PRQR |
6-K filed: Foreign issuer report |
Filing |
— |
| September 23, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| September 23, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| September 23, 2026 |
GOSS |
8-K filed: Other event |
Filing |
— |
| September 23, 2026 |
MBRX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 23, 2026 |
ACIU |
6-K filed: Foreign issuer report |
Filing |
— |
| September 23, 2026 |
LTRN |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 24, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| September 24, 2026 |
ACAD |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 24, 2026 |
VTGN |
8-K filed: Other event |
Filing |
— |
| September 24, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| September 24, 2026 |
KYTX |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 24, 2026 |
COAG |
8-K filed: Leadership change |
Corporate |
— |
| September 24, 2026 |
NGEN |
6-K filed: Foreign issuer report |
Filing |
— |
| September 24, 2026 |
BLRX |
6-K filed: Foreign issuer report |
Filing |
— |
| September 24, 2026 |
LTRN |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 24, 2026 |
CGEM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 25, 2026 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| September 25, 2026 |
VTGN |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 25, 2026 |
NKTR |
8-K filed: Other event |
Filing |
— |
| September 25, 2026 |
STOK |
8-K filed: Leadership change |
Corporate |
— |
| September 25, 2026 |
NGEN |
6-K filed: Foreign issuer report |
Filing |
— |
| September 25, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 25, 2026 |
CELZ |
8-K filed: Material agreement |
Corporate |
— |
| September 27, 2026 |
ONC |
A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy Adults |
Trial Milestone |
Phase 1 |
| September 27, 2026 |
BIIB |
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus |
Trial Milestone |
Phase 3 |
| September 28, 2026 |
MRK |
A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005) |
Trial Milestone |
Phase 1 |
| September 28, 2026 |
BMY |
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) |
Trial Milestone |
Phase 3 |
| September 28, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| September 28, 2026 |
INCY |
A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma |
Trial Milestone |
Phase 2 |
| September 28, 2026 |
NBIX |
8-K filed: Leadership change |
Corporate |
— |
| September 28, 2026 |
MIRM |
8-K filed: Other event |
Filing |
— |
| September 28, 2026 |
FDMT |
8-K filed: Other event |
Filing |
— |
| September 28, 2026 |
KOD |
8-K filed: Other event |
Filing |
— |
| September 28, 2026 |
ADRX |
8-K filed: Other event |
Filing |
— |
| September 28, 2026 |
OCGN |
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease |
Trial Milestone |
Phase 2/Phase 3 |
| September 28, 2026 |
MLTX |
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN) |
Trial Milestone |
Phase 3 |
| September 28, 2026 |
HUMA |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| September 28, 2026 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| September 28, 2026 |
MNOV |
8-K filed: Material agreement |
Corporate |
— |
| September 28, 2026 |
ONCY |
8-K filed: Other event |
Filing |
— |
| September 28, 2026 |
NTHI |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 28, 2026 |
TPST |
8-K filed: Material agreement, Leadership change, Reg FD disclosure |
Corporate |
— |
| September 28, 2026 |
GOSS |
8-K filed: Other event |
Filing |
— |
| September 28, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 28, 2026 |
FATE |
8-K filed: Other event |
Filing |
— |
| September 29, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| September 29, 2026 |
GSK |
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) |
Trial Milestone |
Phase 3 |
| September 29, 2026 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| September 29, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| September 29, 2026 |
SMMT |
8-K filed: Material agreement, Other event |
Corporate |
— |
| September 29, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| September 29, 2026 |
IOVA |
8-K filed: Other event |
Filing |
— |
| September 29, 2026 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| September 29, 2026 |
DYN |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 29, 2026 |
RNAC |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 29, 2026 |
IVVD |
8-K filed: Other event |
Filing |
— |
| September 29, 2026 |
IMNN |
8-K filed: Material agreement |
Corporate |
— |
| September 29, 2026 |
QURE |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 29, 2026 |
PHAT |
8-K filed: Other event |
Filing |
— |
| September 29, 2026 |
ALT |
8-K filed: Leadership change |
Corporate |
— |
| September 29, 2026 |
LRMR |
8-K filed: Leadership change |
Corporate |
— |
| September 29, 2026 |
LXEO |
8-K filed: Acquisition completed |
Corporate |
— |
| September 29, 2026 |
ONCY |
8-K filed: Other event |
Filing |
— |
| September 29, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| September 29, 2026 |
ALDX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 29, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| September 29, 2026 |
BYSI |
8-K filed: Material agreement, Other event |
Corporate |
— |
| September 29, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 29, 2026 |
ALZN |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 30, 2026 |
NVS |
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation |
Trial Milestone |
Phase 1/Phase 2 |
| September 30, 2026 |
REGN |
8-K filed: Leadership change |
Corporate |
— |
| September 30, 2026 |
INCY |
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive |
Trial Milestone |
Phase 2 |
| September 30, 2026 |
SVA |
Phase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies Vaccine |
Trial Milestone |
Phase 3 |
| September 30, 2026 |
BIIB |
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus |
Trial Milestone |
Phase 3 |
| September 30, 2026 |
BMRN |
8-K filed: Material agreement |
Corporate |
— |
| September 30, 2026 |
IBRX |
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer |
Trial Milestone |
Phase 1/Phase 2 |
| September 30, 2026 |
MRNA |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| September 30, 2026 |
KARD |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| September 30, 2026 |
LQDA |
8-K filed: Other event |
Filing |
— |
| September 30, 2026 |
MLTX |
8-K filed: Other event |
Filing |
— |
| September 30, 2026 |
OCS |
6-K filed: Foreign issuer report |
Filing |
— |
| September 30, 2026 |
QURE |
Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS) |
Trial Milestone |
Phase 1/Phase 2 |
| September 30, 2026 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| September 30, 2026 |
HALO |
8-K filed: Leadership change |
Corporate |
— |
| September 30, 2026 |
SGMT |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 30, 2026 |
RADX |
Results filed (20-F) |
Earnings |
— |
| September 30, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| September 30, 2026 |
OTLK |
8-K filed: Listing / standard notice |
Corporate |
— |
| September 30, 2026 |
TCRX |
8-K filed: Leadership change |
Corporate |
— |
| September 30, 2026 |
LTRN |
8-K filed: Material agreement |
Corporate |
— |
| September 30, 2026 |
QTTB |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |